Chauhan Heli, Carruthers Nick, Stemmer Paul, Schneider Bernard P, Moszczynska Anna
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI, USA 48201.
Institute of Environmental Health Sciences and Proteomics Core Facility, 540 East Canfield Ave., Detroit, MI 48202.
bioRxiv. 2024 Jul 23:2024.07.21.604458. doi: 10.1101/2024.07.21.604458.
In recent years, methamphetamine METH misuse in the US has been rapidly increasing and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on the drug, people with MUD develop a variety of neurological problems related to the toxicity of this drug. A variety of molecular mechanisms underlying METH neurotoxicity has been identified, including dysfunction of the neuroprotective protein parkin. However, it is not known whether parkin loss of function within striatal dopaminergic (DAergic) terminals translates into a decrease in DA storage capacity. This study examined the relationship between parkin, its substrate cell division cycle related-1 (CDCrel-1), and vesicular monoamine transporter-2 (VMAT2) in METH neurotoxicity in male Sprague Dawley rats. To also assess individual differences in response to METH's neurotoxic effects, a large group of rats was treated with binge METH or saline and sacrificed 1h or 24h later. This study is the first to show that binge METH alters the levels and subcellular localization of CDCrel-1 and that CDCrel-1 interacts with VMAT2 and increases its levels at the plasma membrane. Furthermore, we found wide individual differences in the responses of measured indices to METH. Proteomic analysis of VMAT-2-associated proteins revealed upregulation of several proteins involved in the exocytosis/endocytosis cycle. The results suggest that at 1h after METH binge, DAergic neurons are engaged in counteracting METH-induced toxic effects, including oxidative stress- and hyperthermia-induced inhibition of synaptic vesicle cycling, with the responses varying between individual rats. Studying CDCrel-1, VMAT2, and other proteins in large groups of outbred rats can help define individual genetic and molecular differences in responses to METH neurotoxicity which, in turn, will aid treating humans suffering from METH use disorder and its neurological consequences.
近年来,美国甲基苯丙胺(METH)滥用现象迅速增加,且尚无美国食品药品监督管理局(FDA)批准的用于治疗甲基苯丙胺使用障碍(MUD)的药物疗法。除了对药物产生依赖外,患有MUD的人还会出现与该药物毒性相关的各种神经问题。已经确定了多种METH神经毒性的分子机制,包括神经保护蛋白帕金(parkin)功能障碍。然而,尚不清楚纹状体多巴胺能(DAergic)终末内的parkin功能丧失是否会导致多巴胺储存能力下降。本研究在雄性斯普拉格-道利大鼠中研究了parkin、其底物细胞分裂周期相关蛋白1(CDCrel-1)和囊泡单胺转运体2(VMAT2)在METH神经毒性中的关系。为了评估对METH神经毒性作用反应的个体差异,一大组大鼠接受了大剂量METH或生理盐水治疗,并在1小时或24小时后处死。本研究首次表明,大剂量METH会改变CDCrel-1的水平和亚细胞定位,且CDCrel-1与VMAT2相互作用并增加其在质膜上的水平。此外,我们发现所测指标对METH的反应存在广泛的个体差异。对VMAT-2相关蛋白的蛋白质组学分析显示,参与胞吐/胞吞循环的几种蛋白上调。结果表明,在METH大剂量给药后1小时,多巴胺能神经元参与对抗METH诱导的毒性作用,包括氧化应激和高热诱导的突触小泡循环抑制,个体大鼠之间的反应有所不同。在大量远交系大鼠中研究CDCrel-1、VMAT2和其他蛋白有助于确定对METH神经毒性反应的个体遗传和分子差异,这反过来将有助于治疗患有METH使用障碍及其神经后果的人类。